Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients.
COVID- 19
DVT prophylaxis
LMWH (low molecular weight heparin)
heparin
in-hospital mortality
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
06
2020
accepted:
10
07
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients. Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant'Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with "standard" prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the "standard" prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089-0.758, p=0.014). Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.
Sections du résumé
BACKGROUND
BACKGROUND
Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients.
METHODS AND RESULTS
RESULTS
Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant'Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with "standard" prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the "standard" prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089-0.758, p=0.014).
CONCLUSIONS
CONCLUSIONS
Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.
Identifiants
pubmed: 32848743
doi: 10.3389/fphar.2020.01124
pmc: PMC7424043
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1124Informations de copyright
Copyright © 2020 Paolisso, Bergamaschi, D’Angelo, Donati, Giannella, Tedeschi, Pascale, Bartoletti, Tesini, Biffi, Cosmi, Pizzi, Viale and Galié.
Références
Ann Intern Med. 2020 Aug 18;173(4):287-296
pubmed: 32459529
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
J Thromb Haemost. 2020 Jul;18(7):1743-1746
pubmed: 32320517
Ann Intern Med. 2020 May 15;:
pubmed: 32422061
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Thromb Haemost. 2020 Aug;18(8):1859-1865
pubmed: 32459046
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
J Clin Invest. 2001 Jul;108(2):169-73
pubmed: 11457867
Front Biosci (Landmark Ed). 2017 Jun 1;22:1867-1883
pubmed: 28410150
Circulation. 2020 Jul 14;142(2):184-186
pubmed: 32330083
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
J Clin Invest. 1982 Mar;69(3):543-53
pubmed: 7037851
N Engl J Med. 2020 Jun 18;382(25):2411-2418
pubmed: 32379955
Thromb Res. 2020 Jul;191:145-147
pubmed: 32291094